Sinopharm Group Co (HKSE:01099) Net Change in Cash : HK$10,147 Mil (TTM As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sinopharm Group Co's Net Change in Cash for the six months ended in Jun. 2024 was HK$-22,044 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was HK$10,147 Mil.

Sinopharm Group Co Net Change in Cash Historical Data

The historical data trend for Sinopharm Group Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co Net Change in Cash Chart

Sinopharm Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-1,231.84

13,023.52

-8,141.29

13,056.85

9,392.19

Sinopharm Group Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Change in Cash	Get a 7-Day Free Trial															-13,343.58	25,768.84	-22,799.31	32,191.46	-22,044.13

Sinopharm Group Co Net Change in Cash Calculation

Sinopharm Group Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	18783.498	+	-1033.112	+	-8360.813	+	2.613
	=	9,392

Sinopharm Group Co's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -44131.466 + -1118.004 + 23201.404 + 3.932

= -22,044

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$10,147 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (HKSE:01099) » Definitions » Net Change in Cash

Comparable Companies

HKSE:00314 HKSE:02192 HKSE:09955 HKSE:01931 HKSE:02289 HKSE:00673 HKSE:06833 HKSE:00718 HKSE:08372 HKSE:00401 MCK COR CAH HSIC SHSE:601607 MIL:AMP NZSE:EBO XSWX:GALE TSE:7459 TSE:2784

Traded in Other Exchanges

SHTDY:USA SHTDF:USA X2S:Germany

Address

No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website

http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Executives

Blackrock, Inc. 2201 Interest of corporation controlled by you

Lazard Asset Management Llc 2102 Investment manager

Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you

Citigroup Inc. 2502 Approved lending agent

Fmr Llc 2201 Interest of corporation controlled by you

Sinopharm Group Co Headlines

No Headlines

Blackrock, Inc.	2201 Interest of corporation controlled by you
Lazard Asset Management Llc	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2502 Approved lending agent
Fmr Llc	2201 Interest of corporation controlled by you